Novavax Earns $125 Million Milestone Payment From Sanofi Vaccine Trial
Novavax earned a $125 million milestone payment from Sanofi's Phase 3 vaccine trial in Europe.
Novavax earned a $125 million milestone payment from Sanofi's Phase 3 vaccine trial in Europe.